tiprankstipranks
Idorsia Ltd (CH:IDIA)
:IDIA
Switzerland Market
IDIA
Idorsia Ltd
RESEARCH TOOLSreports
Want to see CH:IDIA full AI Analyst Report?

Idorsia Ltd (IDIA) Stock News & Sentiment

13 Followers
Premium
Ratings
Buy Rating Reaffirmed on Daridorexant Growth Prospects; 12‑Month Price Target Maintained at $5
3d ago
Idorsia: Positive Pediatric Daridorexant Data and Neurodevelopmental Expansion Drive Buy Rating and CHF5 Target
Premium
Ratings
Idorsia: Positive Pediatric Daridorexant Data and Neurodevelopmental Expansion Drive Buy Rating and CHF5 Target
2M ago
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
Premium
Ratings
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
2M ago
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
Premium
Ratings
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
3M ago
Idorsia Earnings Call Signals Turnaround, Risks Linger
Premium
Company Announcements
Idorsia Earnings Call Signals Turnaround, Risks Linger
3M ago
Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target
Premium
Ratings
Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target
4M ago
Idorsia: Latin America QUVIVIQ Deal and Pipeline Optionality De‑Risk Path to Profitability, Supporting Reiterated Buy Rating
Premium
Ratings
Idorsia: Latin America QUVIVIQ Deal and Pipeline Optionality De‑Risk Path to Profitability, Supporting Reiterated Buy Rating
4M ago
More CH:IDIA News >

IDIA News on the Web

Buy Rating Reaffirmed on Daridorexant Growth Prospects; 12‑Month Price Target Maintained at $5
TipRanks News
Bullish
Idorsia Ltd (IDIA) Receives a Rating Update from a Top Analyst
TipRanks News
Bullish
Idorsia: Positive Pediatric Daridorexant Data and Neurodevelopmental Expansion Drive Buy Rating and CHF5 Target
TipRanks News
Neutral
Idorsia's Daridorexant Shows Positive Phase 2 Results In Paediatric Insomnia; Stock Up
rttnews
Bullish
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
TipRanks News
Bullish
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
TipRanks News
Bullish
Idorsia price target lowered to CHF 5 from CHF 6 at H.C. Wainwright
TipRanks News
Neutral
Kepler Capital Sticks to Their Buy Rating for Idorsia Ltd (IDIA)
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
CH:IDIA
Sector Average
Media Buzz
This Week1 articles
Weekly Average0.5 articles
News Sentiment
This Week100%
Sector Average81%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CH:IDIA’s Media Buzz Sentiment?
1 articles about CH:IDIA were published this week. In an average week, 0.5 articles are published.
    What is CH:IDIA’s weekly average amount of articles?
    In an average week, 0.5 articles about CH:IDIA are published.
      What is CH:IDIA’s News Sentiment?
      100% of articles about CH:IDIA were positive this week, compared to its sector average of 81%.
        General Stocks that are Trending in the News
        TCCTCC Concept Ltd
        CFRCompagnie Financiere Richemont SA
        EDRYEuroDry
        0QVPElior Group SA
        MRVMarvell Technology Inc Sponsored Canadian Depository Receipt Hedged
        Showing the stocks with the most bullish news sentiment over the past week